{"id":"heparin-fixed-doses","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin binds to and enhances the activity of antithrombin III, a natural inhibitor of coagulation. This complex rapidly inactivates thrombin (Factor IIa) and Factor Xa, preventing the formation of fibrin clots and the propagation of thrombosis. Fixed-dose heparin formulations provide standardized anticoagulation for prophylaxis and treatment of thromboembolic disorders.","oneSentence":"Heparin is an anticoagulant that inhibits blood clotting by potentiating antithrombin III, which inactivates thrombin and other clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:28.989Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis in surgical patients"},{"name":"Treatment of acute venous thromboembolism"},{"name":"Prevention of clotting in extracorporeal circulation during anesthesia"}]},"trialDetails":[{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT07288489","phase":"PHASE3","title":"Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","status":"NOT_YET_RECRUITING","sponsor":"VarmX B.V.","startDate":"2026-03","conditions":"Blood Loss, Surgical, Coagulation Disorder","enrollment":800},{"nctId":"NCT05625932","phase":"PHASE3","title":"TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2023-03-02","conditions":"Colorectal Cancer Metastatic, Thromboembolism","enrollment":232},{"nctId":"NCT06818279","phase":"PHASE2, PHASE3","title":"Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-31","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":120},{"nctId":"NCT03581877","phase":"PHASE4","title":"Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2019-01-28","conditions":"Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism","enrollment":31},{"nctId":"NCT05426031","phase":"PHASE4","title":"Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-06-28","conditions":"Coagulation; Intravascular","enrollment":130},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":"COVID, Thrombosis, Pulmonary Embolism","enrollment":1000},{"nctId":"NCT04725201","phase":"PHASE4","title":"Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization","status":"UNKNOWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-05-24","conditions":"Amputation; Traumatic, Hand","enrollment":188},{"nctId":"NCT05944107","phase":"PHASE4","title":"Anticoagulation Management in Complex Cardiac Surgery","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2021-01-01","conditions":"Extracorporeal Circulation","enrollment":65},{"nctId":"NCT03516656","phase":"EARLY_PHASE1","title":"Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-03-23","conditions":"Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism","enrollment":20},{"nctId":"NCT05382481","phase":"NA","title":"Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2022-05-16","conditions":"Venous Thromboembolism","enrollment":858},{"nctId":"NCT04558892","phase":"PHASE2, PHASE3","title":"Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.","status":"TERMINATED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2015-10-01","conditions":"Nephrotic Syndrome","enrollment":65},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT03309137","phase":"NA","title":"Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients","status":"COMPLETED","sponsor":"Alison Fox-Robichaud","startDate":"2017-11-19","conditions":"Infection, Heart; Surgery, Heart, Functional Disturbance as Result, Bacteremia","enrollment":100},{"nctId":"NCT04305756","phase":"NA","title":"Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-06-12","conditions":"Thromboembolism, Postpartum DVT, Thrombosis","enrollment":146},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT02486666","phase":"PHASE3","title":"Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2016-03","conditions":"Venous Thromboembolism","enrollment":20},{"nctId":"NCT03251963","phase":"PHASE2","title":"Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2017-09-15","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Surgery","enrollment":131},{"nctId":"NCT04435912","phase":"EARLY_PHASE1","title":"Hydrocortisone Per-treatment Decrease Side Effects of Protamine Sulfate","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2019-07-04","conditions":"Blood Pressure, Heart Rate, Airway Pressure","enrollment":200},{"nctId":"NCT04063423","phase":"","title":"Non- Clinical Coagulation Activation During Hemodialysis","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-10-25","conditions":"Kidney Diseases, End Stage Renal Disease, Hemodialysis Complication","enrollment":32},{"nctId":"NCT02970032","phase":"EARLY_PHASE1","title":"Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin","status":"COMPLETED","sponsor":"University of Utah","startDate":"2016-11-10","conditions":"Deep-Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism","enrollment":20},{"nctId":"NCT03218514","phase":"","title":"Venous Thromboprophylaxis in Bariatric Surgery","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2014-07","conditions":"Obesity","enrollment":118},{"nctId":"NCT01621243","phase":"PHASE1, PHASE2","title":"M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer","status":"TERMINATED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2012-05","conditions":"Metastatic Pancreatic Cancer","enrollment":128},{"nctId":"NCT02966080","phase":"NA","title":"Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2016-12","conditions":"Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding","enrollment":""},{"nctId":"NCT00182403","phase":"PHASE3","title":"Fixed Dose Heparin Study","status":"COMPLETED","sponsor":"McMaster University","startDate":"1998-09","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":866},{"nctId":"NCT01651780","phase":"PHASE3","title":"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2012-10","conditions":"Severe Aortic Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve Replacement","enrollment":803},{"nctId":"NCT01608347","phase":"PHASE4","title":"Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies","status":"COMPLETED","sponsor":"Omar Mamdouh Shaaban","startDate":"2010-01","conditions":"Recurrent Miscarriage","enrollment":228},{"nctId":"NCT00351663","phase":"PHASE4","title":"The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2007-02","conditions":"Venous Thrombosis, Critical Illness","enrollment":39},{"nctId":"NCT01068795","phase":"NA","title":"Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2009-07","conditions":"Fetal Demise, Fetal Growth Restriction, Preeclampsia","enrollment":144},{"nctId":"NCT02477072","phase":"NA","title":"Optimized Heparin Regimen in Vascular Surgery","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2015-09","conditions":"Peripheral Revascularisation","enrollment":32},{"nctId":"NCT02070237","phase":"PHASE1","title":"Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis","status":"COMPLETED","sponsor":"MemorialCare Health System","startDate":"2013-08","conditions":"Obesity, Obesity, Morbid, Pregnancy","enrollment":90},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT01956955","phase":"PHASE4","title":"Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Ataturk University","startDate":"2011-01","conditions":"This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.","enrollment":150},{"nctId":"NCT00932100","phase":"PHASE2","title":"A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Regado Biosciences, Inc.","startDate":"2009-07","conditions":"Acute Coronary Syndrome (ACS)","enrollment":640},{"nctId":"NCT01267487","phase":"PHASE4","title":"Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"SANE-Society of Anesthesiology","startDate":"2009-07","conditions":"Cardiac Surgery, Cardiopulmonary Bypass, Anticoagulation","enrollment":240},{"nctId":"NCT00587444","phase":"PHASE3","title":"Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-06","conditions":"Postoperative Hemorrhage","enrollment":270},{"nctId":"NCT00711308","phase":"PHASE4","title":"Tinzaparin in the Treatment of the Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Complejo Hospitalario Xeral-Calde","startDate":"2005-04","conditions":"Acute Pulmonary Embolism","enrollment":102},{"nctId":"NCT00689520","phase":"PHASE4","title":"Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2002-01","conditions":"Venous Thromboembolism","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":107,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heparin fixed doses","genericName":"Heparin fixed doses","companyName":"SANE-Society of Anesthesiology","companyId":"sane-society-of-anesthesiology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heparin is an anticoagulant that inhibits blood clotting by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Thromboembolism prophylaxis in surgical patients, Treatment of acute venous thromboembolism, Prevention of clotting in extracorporeal circulation during anesthesia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}